Pituitary stalk interruption syndrome(PSIS) typically manifests initially as short stature due to growth hormone deficiency(GHD). Untreated chronic GHD may induce metabolic disturbances, leading to non-alcoholic fatty liver disease with rapid progression to liver cirrhosis. Liver cirrhosis can subsequently cause hepatopulmonary syndrome, resulting in hypoxemia and dyspnea. This article reports a case of a young male presenting with short stature, dyspnea, liver cirrhosis, and hepatopulmonary syndrome, ultimately diagnosed with PSIS. Following recombinant human growth hormone(rhGH) and other hormonal replacement therapies, the patient exhibited improvement in hepatic steatosis and fibrosis, with alleviation of dyspnea. Through analysis of this case, we provide clinical insights for diagnosing and managing cirrhosis and hepatopulmonary syndrome in such patients, highlighting that early diagnosis and timely initiation of rhGH replacement therapy can improve prognosis and quality of life.

Pituitary stalk interruption syndrome(PSIS) typically manifests initially as short stature due to growth hormone deficiency(GHD). Untreated chronic GHD may induce metabolic disturbances, leading to non-alcoholic fatty liver disease with rapid progression to liver cirrhosis. Liver cirrhosis can subsequently cause hepatopulmonary syndrome, resulting in hypoxemia and dyspnea. This article reports a case of a young male presenting with short stature, dyspnea, liver cirrhosis, and hepatopulmonary syndrome, ultimately diagnosed with PSIS. Following recombinant human growth hormone(rhGH) and other hormonal replacement therapies, the patient exhibited improvement in hepatic steatosis and fibrosis, with alleviation of dyspnea. Through analysis of this case, we provide clinical insights for diagnosing and managing cirrhosis and hepatopulmonary syndrome in such patients, highlighting that early diagnosis and timely initiation of rhGH replacement therapy can improve prognosis and quality of life.

The latest epidemiological data suggests that the situation of adult diabetes in China is severe, and metabolic diseases have become significant chronic illnesses that have a serious impact on public health and social development. After more than six years of practice, the National Metabolic Management Center(MMC) has developed distinctive approaches to manage metabolic patients and has achieved a series of positive outcomes, continuously advancing the standardized diagnosis and treatment model. In order to further improve the efficiency, based on the first edition, the second edition guideline was composed by incorporating experience of the past six years in conjunction with the latest international and domestic guidelines.

Diabetic microvascular disease is a severe complication of diabetes mellitus (DM).There are many hypoth-esis for its mechanisms.This overview aimed at effect of C-peptide,coagulant factors,platelet and D-dimer in dia-betic microvascular disease,and provided evidence for its prevention and treatment in clinic.

Nonalcoholic fatty liver disease (NAFLD),which is often complicated in patients with type 2 diabetes mellitus,is a kind of metabolic stress-induced liver injury closely related with insulin resistance (IR)and genetic sus-ceptibility.Its mechanism is very complicated and there are no specific drugs now.This article made an overview on NAFLD mechanism.